FDA Authorizes Higher-Dose Vials For Moderna Vaccine

FDA Authorizes Higher-Dose Vials For Moderna Vaccine

They also released the results of a trial of 800 participants in South Africa, where a new variant of the coronavirus is circulating.

"This issue was discussed with State representatives and experts and per recommendation of National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) no fresh registration will be allowed in these categories, " Mr. Bhushan said.

Marcelo Queiroga, Brazil's fourth health minister since the pandemic began, said he hoped to include veterinary facilities that make vaccines for pets.

The results follow separate data that showed the vaccine is safe and effective in 12- to 15-year olds, paving the way for the drugmakers to seek USA and European approvals for this group.

Jordanian military warns king’s half-brother to stop actions undermining stability
Abdullah has ruled Jordan since the 1999 death of of his father, King Hussein, who ruled the country for close to half a century. After the arrests, the Saudi royal court expressed full support for King Abdullah, as well as Egypt, Lebanon and Bahrain.

It comes as a separate UK-based study found the Pfizer vaccine produces an "off the scale" immune response that is likely to protect against the Brazilian variant of Covid-19, with scientists in the United Kingdom reporting strong immune responses in older people who had received two shots of the Pfizer vaccine. For the study, the team conducted a survey of 1,090 healthcare workers at Cedars-Sinai who had received the Pfizer-BioNTech vaccine.

Since that initial analysis, more COVID-19 cases have accrued, increasing to 927 as of March 13 from the previous 170. The firms said the data demonstrates the vaccine's high efficacy against this variant. "The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine's overall effectiveness".

This was welcomed by the drugmakers, because in February they said a laboratory test suggested that their vaccine produced lower levels of antibodies against this strain. "My general feeling is that given the contractual relationships that we have with a number of companies, that we have enough vaccine to fulfill all of our needs without invoking AstraZeneca". The approach has been tested against other viruses and studies in animals and people show they stimulate a strong and broad immune response.

The vaccine, developed by American pharmaceutical giant Pfizer and its German partner BioNTech, received emergency use authorization in December from the Food and Drug Administration, which is only granted in special circumstances. As part of the process, they both must continue their clinical trials for two years and will continue to report safety and efficacy data as they get it.

Related Articles